Biopharmaceutical company MicroCures partnered Feb. 19 with the Henry M. Jackson Foundation for the Advancement of Military Medicine to study spinal cord regeneration after trauma.
Researchers from the U.S. Department of Defense will evaluate MicroCures' lead product, siFi2, in animal models with spinal cord injuries.
Intended to improve recovery after trauma, siFi2 is a small interfering ribonucleic acid therapeutic that is applied topically.
Spearheaded by Kimberly Byrnes, PhD, of the Uniformed Services University of the Health Sciences in Bethesda, Md., researchers will explore the use of siFi2 in driving axon regeneration and functional recovery.